Abstract

Simple SummaryBreast cancer is a common malignancy, but the understanding of its cellular and molecular mechanisms is limited. The ZFHX3 transcription factor regulates mammary epithelial cells’ proliferation and differentiation by interacting with estrogen and progesterone receptors. Both these receptors play crucial roles in breast cancer development, but whether ZFHX3 also impacts breast cancer is unknown. In this study, the authors aim to determine if ZFHX3 promotes breast cancer cells’ proliferation and tumor growth and explore the underlying cellular and molecular mechanisms. Higher ZFHX3 expression is associated with worse patient survival in breast cancer, ZFHX3 promotes the proliferation and tumor growth of breast cancer cells, and several breast cancer stem cell factors appear to be involved in the role of ZFHX3 in breast cancer growth. The findings suggest that ZFHX3 is a novel oncogenic molecule promoting breast cancer development. Such a molecule could provide novel opportunities for the treatment of breast cancer.Breast cancer is a common malignancy, but the understanding of its cellular and molecular mechanisms is limited. ZFHX3, a transcription factor with many homeodomains and zinc fingers, suppresses prostatic carcinogenesis but promotes tumor growth of liver cancer cells. ZFHX3 regulates mammary epithelial cells’ proliferation and differentiation by interacting with estrogen and progesterone receptors, potent breast cancer regulators. However, whether ZFHX3 plays a role in breast carcinogenesis is unknown. Here, we found that ZFHX3 promoted the proliferation and tumor growth of breast cancer cells in culture and nude mice; and higher expression of ZFHX3 in human breast cancer specimens was associated with poorer prognosis. The knockdown of ZFHX3 in ZFHX3-high MCF-7 cells decreased, and ZFHX3 overexpression in ZFHX3-low T-47D cells increased the proportion of breast cancer stem cells (BCSCs) defined by mammosphere formation and the expression of CD44, CD24, and/or aldehyde dehydrogenase 1. Among several transcription factors that have been implicated in BCSCs, MYC and TBX3 were transcriptionally activated by ZFHX3 via promoter binding, as demonstrated by luciferase-reporter and ChIP assays. These findings suggest that ZFHX3 promotes breast cancer cells’ proliferation and tumor growth likely by enhancing BCSC features and upregulating MYC, TBX3, and others.

Highlights

  • Breast cancer is a common malignancy among women [1]

  • We found that ZFHX3 promotes breast cancer cell proliferation and tumor growth, and the underlying cellular and molecular mechanisms involve breast cancer stem cells (BCSCs)-like features and transcriptional activation of MYC

  • To test whether ZFHX3 modulates breast cancer cell proliferation and tumorigenicity, we first surveyed the levels of endogenous ZFHX3 expression in 5 breast cell lines by western blotting

Read more

Summary

Introduction

Breast cancer is a common malignancy among women [1]. Estrogen receptor alpha (ER) signaling is the defining and driving force in most breast cancers, and selective ER modulator (SERM) therapy is widely used to treat breast cancer. While other signaling pathways modulate breast carcinogenesis, the expression status of ER, progesterone receptor (PR), human epidermal growth factor receptor 2. Most breast cancers are luminal tumors and a higher Ki67 index distinguishes luminal B from luminal A tumors [4], ER+ /PR− luminal tumors have a unique gene expression signature. They are less responsive than ER+ /PR+ tumors to SERM therapy [5]. While PR can be transcriptionally induced by ER and PR can cause or promote breast carcinogenesis [6,7,8], PR has unique ER-independent functions in luminal breast cancer [7,9]. It is still an important task to understand the molecular modulators of breast cancer

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call